Bristol-Myers Squibb Co (NYSE:BMY) was the recipient of a significant increase in short interest during the month of February. As of February 28th, there was short interest totalling 74,111,887 shares, an increase of 21.6% from the February 15th total of 60,972,039 shares. Currently, 4.5% of the shares of the company are sold short. Based on an average daily trading volume, of 24,159,361 shares, the short-interest ratio is currently 3.1 days.
Bristol-Myers Squibb stock opened at $49.96 on Friday. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.50 and a current ratio of 1.61. Bristol-Myers Squibb has a 12 month low of $44.30 and a 12 month high of $67.44. The company has a market capitalization of $80.88 billion, a price-to-earnings ratio of 12.55, a P/E/G ratio of 2.22 and a beta of 0.81.
Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, January 24th. The biopharmaceutical company reported $0.94 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.85 by $0.09. Bristol-Myers Squibb had a return on equity of 48.99% and a net margin of 21.95%. The business had revenue of $5.97 billion for the quarter, compared to analyst estimates of $5.95 billion. During the same quarter in the prior year, the firm posted $0.68 EPS. The business’s quarterly revenue was up 9.6% compared to the same quarter last year. Sell-side analysts expect that Bristol-Myers Squibb will post 4.15 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 1st. Shareholders of record on Friday, April 5th will be given a $0.41 dividend. The ex-dividend date of this dividend is Thursday, April 4th. This represents a $1.64 annualized dividend and a yield of 3.28%. Bristol-Myers Squibb’s dividend payout ratio is presently 41.21%.
Institutional investors have recently added to or reduced their stakes in the business. Capital Financial Planning LLC acquired a new position in shares of Bristol-Myers Squibb during the 4th quarter worth approximately $28,000. Well Done LLC acquired a new position in shares of Bristol-Myers Squibb during the 4th quarter worth approximately $30,000. Riverview Trust Co acquired a new position in shares of Bristol-Myers Squibb during the 4th quarter worth approximately $33,000. Portfolio Solutions LLC acquired a new position in shares of Bristol-Myers Squibb during the 4th quarter worth approximately $37,000. Finally, Gantzert Investment Co. LLC ADV acquired a new position in shares of Bristol-Myers Squibb during the 4th quarter worth approximately $39,000. Institutional investors and hedge funds own 73.35% of the company’s stock.
A number of equities research analysts recently commented on BMY shares. BMO Capital Markets reiterated a “buy” rating and issued a $60.00 target price on shares of Bristol-Myers Squibb in a research report on Thursday, January 3rd. Societe Generale upgraded Bristol-Myers Squibb from a “sell” rating to a “buy” rating in a research report on Tuesday, January 15th. Zacks Investment Research upgraded Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $60.00 target price on the stock in a research report on Tuesday, March 5th. Edward Jones lowered Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research report on Friday, January 4th. Finally, Morgan Stanley set a $54.00 target price on Bristol-Myers Squibb and gave the company a “hold” rating in a research report on Thursday, December 20th. One equities research analyst has rated the stock with a sell rating, eleven have given a hold rating and eight have assigned a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $59.40.
ILLEGAL ACTIVITY NOTICE: “Bristol-Myers Squibb Co (BMY) Short Interest Up 21.6% in February” was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this article on another site, it was stolen and republished in violation of US and international trademark & copyright laws. The original version of this article can be read at https://www.dispatchtribunal.com/2019/03/17/bristol-myers-squibb-co-bmy-short-interest-up-21-6-in-february.html.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.
Featured Story: Options Trading – What is a Straddle?
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.